The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L.
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tomonari Sasaki
Consulting or Advisory Role - Fujifilm
Other Relationship - Fujifilm
 
Takeharu Yamanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Serono; MSD; Taiho Pharmaceutical; Takeda
 
Naonobu Kunitake
No Relationships to Disclose
 
Junichi Shimizu
No Relationships to Disclose
 
Takeshi Kodaira
Speakers' Bureau - Kyowa Hakko Kirin; Merck Serono; Otsuka
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Takuyo Kozuka
No Relationships to Disclose
 
Toshiaki Takahashi
Speakers' Bureau - AstraZeneca; Lilly; Ono Pharmaceutical
 
Hideyuki Harada
No Relationships to Disclose
 
Naruo Yoshimura
No Relationships to Disclose
 
Shinichi Tsutsumi
No Relationships to Disclose
 
Hiromoto Kitajima
No Relationships to Disclose
 
Masaaki Kataoka
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - Kyowa Hakko Kirin; Taiho Pharmaceutical
Speakers' Bureau - Kyowa Hakko Kirin; Taiho Pharmaceutical
Research Funding - Kyowa Hakko Kirin (Inst); Taiho Pharmaceutical (Inst)
 
Yasumasa Nishimura
No Relationships to Disclose
 
Yoichi Nakanishi
Research Funding - Taiho Pharmaceutical